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ABSTRACT 
The Effects of Metaphylaxis and Milk Replacer Additives on Health and Growth of 
Neonatal Holstein Bull Calves. (April 2010) 
 
Katherine Grace DeHaan 
Department of Animal Science 
Texas A&M University 
 
Research Advisor: Dr. Glenn A. Holub 
Department of Animal Science 
 
 
 
A study evaluating the effects of metaphylaxis antibiotics and milk replacer additives on 
the health and development of Holstein bull calves (n=52; mean body weight=42.28 kg 
+ 3 kg; starting age <3 days) was conducted. The calves were placed into a completely 
random 3 x 4 factorial design with each group receiving either tilmicosin phosphate 
(TIL), ceftiofur crystalline free acid (CEF), or saline solution (CON) injected 
subcutaneously into the neck area. For the duration of the study, the calves also received 
a commercial milk replacer powder (22% Crude Protein / 20% Crude Fat) fed at 1.1% 
BW. Within metaphylaxis treatment, calves were randomly assigned to receive either: 1) 
4 g/d for 7 d and then 2 g/d for 14 d of an egg-based probiotic (PR); 2) 2 g/d of 96% 
betaine (BE); 3) both PR and BE (BP); or 4) no additives .  
 
The calves were housed in individual fiberglass hutches with commercial calf starter and 
water provided ad libitum. The body weight of each calf was recorded twice weekly in 
addition to daily recordings of fecal scores (1 = firm to 4 = watery) for 54 days. Medical 
treatments provided to each calf for scours, respiratory distress, or febrile events were 
 iv
recorded daily. The cumulative response of these incidences were analyzed and used as 
an index of morbidity. None of the additive effects were significant for any of the 
measured variables. The use of metaphylaxis did not significantly affect the average 
daily gain (P>0.60) as the average daily gain was ~ 0.45 kg. However, when examining 
fecal scores, CEF and TIL significantly reduced the average fecal score over the control 
((1.85 vs. 1.97 vs. 2.20 respectively) (P<0.01)). The incidences of neither fever nor 
respiratory issues (P>0.20) were influenced dramatically by metaphylaxis. Overall, the 
average treatments for fever was only 0.66 events and 0.39 events for respiratory distress 
for all calves. Metaphylaxis did not influence the occurrence of scours (fecal score >2) 
(P>0.87). Other than fecal score, these results indicate the use of metaphylaxis did not 
enhance productivity or reduce morbidity of Holstein neonatal bull calves. 
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NOMENCLATURE 
 
ADG    Average Daily Gain 
APT    Adequate Passive Transfer 
BE    Betaine 96% 
BP    Protimax® then Betaine 96% 
BR    Protimax® 
BRD    Bovine Respiratory Disease 
BW    Body Weight 
CEF    Ceftiofur Crystalline Free Acid (Excede®) 
CON    Saline Solution  
IgG    Immunoglobin 
MG    Metaphylactic Groups 
MRA    Milk Replacer Additive Groups 
MG/MRA   Metaphylaxis/ Milk Replacer Additive Interaction  
NA    No Additional Supplement 
RR    Respiratory Rate 
TIL    Tilmicosin Phosphate (Micotil®) 
TSP    Total Serum Protein 
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CHAPTER I 
INTRODUCTION 
 
The dairy business is one of the most rapidly growing and dynamic industries in Texas. 
There are approximately 125.6 million cows used for milk production in the world. In 
the United States, the average dairy herd size is 121.5 milk cows, which has increased 
from 93.8 milk cows in 2001 and has more than doubled the average of 53.9 milk cows 
in 1991 (USDA, 2007). Along with the enhancement in cattle numbers, comes the 
increase in calf numbers. Calf management protocols have been a topic of concern and 
frustration among dairy producers for years, whether calves are raised on a small or large 
scale dairy farm or calf ranch. The most effective calf rearing methods are still being 
explored and decided today. 
 
Dairy producers raise and condition their calves to serve as either heifer replacements, 
veal, steers for beef production, or bulls used for reproduction. Results of recent studies 
have focused attention on calf rearing programs which provide proper care and optimize 
health during the pre-weaning to post-weaning phases. Drackley (2000), indicated that 
the pre-weaning phase is the best time to optimize genetic growth.  
 
 
____________ 
This thesis follows the style of Journal of Dairy Science. 
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This is based on studies showing current calf programs compromise the potential of 
dairy calves during this important time. The most ideal time to most efficiently optimize 
calf growth is during the first 2 months of life (Chester-Jones et al., 2004). 
 
The practice of using metaphylaxis (mass medication application) is common in the beef 
industry to sufficiently manage highly stressed, newly shipped cattle, whereas the 
addition of a milk replacer additive is used throughout the dairy industry to reach the 
same result. Could combining these practices result in better herd health and lower 
mortality and morbidity rates when administered to neonatal Holstein bull calves? This 
study focused on using metaphylaxis and milk replacer additive to treat calves. Factors 
such as morbidity, mortality, body weight (BW), fecal score, average daily gain (ADG), 
and number of treatments for scours, respiratory symptoms, and febrile events were 
recorded and evaluated to help answer this question. 
 
Metaphylaxis  
A metaphylactic agent (typically an antibiotic) can be used as both a prophylactic and a 
therapeutic. The term prophylaxis indicates an antibiotic is used as a preventative 
therapy while therapeutic describes its use in disease treatment. Generally, metaphylactic 
treatments are used to effective manage newly received, highly stressed cattle more 
effectively than without treatment. Newly transported cattle become more susceptible to 
disease as their stress levels increase drastically during shipping. Furthermore, they are 
usually commingled with cattle from various locations which increases the likelihood of 
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exposure to pathogens of which they have no immunity. The use of metaphylaxis helps 
reduce these chances, primarily Bovine Respiratory Disease (BRD), especially for cattle 
which are not properly vaccinated. However, the use of metaphylactic therapy in the 
dairy industry is uncommon, especially in neonatal calves.  
 
In the beef industry, research using metaphylactic therapy has been proven to reduce the 
occurrences of diseases in cattle, improve performance and gain, and reduce morbidity 
(Booker et al., 2006; Galyean et al., 1995; Guthrie et al., 2004). In a study conducted by 
Galyean et al. (1995), tilmicosin phosphate was used as a metaphylactic agent. The 
results indicated a positive result with little to no treatment for BRD in the herd. 
Lofgreen (1983) conducted a study using oxytetracycline and sulfadimethoxine as 
metaphylactic agents. This study’s results demonstrated a 21% reduction in treatments 
for morbidity when given oxytetracycline and a 20% reduction for calves treated with 
sulfadimethoxine. Booker et al. (2006) discovered similar results with the use of 
ceftiofur crystalline free acid. The ceftiofur crystalline free acid group had significantly 
lower mortality and chronicity rates with a significantly higher average daily gain. 
 
Feed intake and ADG 
Feed intake and ADG are also factors negatively affected by stress and morbidity. When 
these aspects are suppressed, the final may be reduced or of lesser quality, in addition, 
the production costs may be increased. With the use of metaphylaxis to alleviate stress 
and increase health, feed intake and ADG can also improve. In a study conducted by 
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Lofgreen (1983), results showed metaphylaxis significantly (P<.05) increased feed 
intake and ADG when compared to the control group (no antibiotic). Feed intake 
increased from 4.48 kg/day in the non-antibiotic group to 4.65 kg/day in the antibiotic 
group. ADG was 1.11 kg/d in the antibiotic group and .99 kg/d in the non-antibiotic 
group. Cusack (2004) found similar results when using tilmicosin and oxytetracycline. 
Calves treated with tilmicosin (P<0.05) had a significantly higher ADG (1.67 
kg/animal/d) versus calves treated with oxytetracycline (1.59 kg/animal/d) and non-
antibiotic (1.59 kg/animal/d). 
 
Milk replacer additives 
Milk Replacer Additives have been shown to increase feed intake as well as ADG in 
addition to aiding the immune system. There have been many ideas as to which extra 
nutritional milk replacer supplements are the most beneficial and effective. Two such 
additives are Protimax® and Betaine 96%. Protimax®   (Trouw Nutrition)  (43% CP, 
30% CF) is composed of pasteurized dried egg mixed with antibodies and other 
nutrients. It is labeled to increase the effectiveness of the neonatal immune system. 
Betaine 96% is a trimethlglycine compound found to aid in feed efficiency and in the 
reduction of the incidence of scours. Betaine is a methylating form of choline and serves 
as a replacement for choline in rations.  As of this time, there is no sound documentation 
for calf management as to the effects, positive or detrimental, of adding either 
formulation. 
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  CHAPTER II 
  METHODOLOGY 
 
Sixty Holstein bull calves were purchased from two dairy farms located in the Texas 
Panhandle. During the initial stages of the project however, eight were culled due to 
health reasons leaving the project with fifty-two. In order to be placed into the 
experiment, the calves had to meet the following standards: considered true Holstein by 
color and markings, be three to five days of age at the time of purchase, fed colostrum no 
later than two hours after they were born, and weigh approximately 45 kg. The duration 
of the trial was 8 weeks (56 days) and took place during the summer months of June-
September in Brazos County, Texas.  
 
Upon arrival to the research site, the calves (3-4 days old) were processed immediately. 
This included recording measurements of: body weight (BW), immunoglobulin (IgG) 
levels, and Total Serum Protein (TSP) levels. These levels were evaluated in order to 
insure adequate passive transfer of immunity as well as to assign the calves a specific 
experimental protocol. For the first 2 days, the calves went through an adaptation period 
in which they received 4.00 L of milk replacer per day (Land O’ Lakes Maxi Care 25% 
crude protein, 20% crude fat) with 2.00 L given in the morning and 2.00 L given in the 
evening. For the subsequent 9 days, 0.45 kg/calf/day of milk replacement powder was 
administered followed by 1.1% of BW adjusted weekly for each treatment group’s mean 
beginning on day 10. Each group also received ad libitum water and 18% CP calf starter 
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(Calf Niblets, Gore Bros. Inc., Comanche, TX). Throughout the experiment, the calves 
were individually housed in fiberglass hutches (Calftel®) spaced 3 m apart to prevent 
spread of diseases. Post-adaptation, each calf received the previously assigned protocol. 
Additionally, a 7-way clostridium vaccine (Agri-labs, Schering-Plough Animal Health 
Corp., Union, NJ) was administered subcutaneously on day 10 to prevent Clostridial 
species diseases (chauvoei, septicum, novyi, sordellii, perfringens Types C & D). 
 
Two metaphylactic agents (antibiotics) were used: tilmicosin phosphate (TIL) and 
ceftiofur crystalline free acid (CEF). Metaphylaxis treatments were administered on day 
2 of the study. Three groups were stratified to effectively evaluate the outcome of the 
antibiotic use. Group 1 received TIL (Micotil ®),(Elanco Animal Health, Indianapolis, 
IN), (10 mg CE/kg, 1.5 mL/45.36 kg) administered subcutaneously in the neck area, 
Group 2 received CEF (Excede ®),(Pfizer Animal Health, New York, NY), (6.6 mg 
CE/kg, 1.5 mL/45.36 kg) administered subcutaneously in the posterior base of the ear, 
and group 3 received saline solution (CON),(1.5mL) administered subcutaneously in the 
neck area to serve as the control group.  
 
The calves were fed 2.00 L of milk replacer (Land O’ Lakes Maxi Care 25% crude 
protein, 20% crude fat) every twelve hours at 0600 h and 1800 h. Milk replacer was 
prepared by mixing the powder with water at 43.00°C using an electric mixer. In 
addition, the calves received a supplement treatment added to the milk replacer. The two 
supplements used were: Protimax ® (43% CP, 30% CF), (Trouw Nutrition, Highland,IL) 
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and Betaine 96%. The supplements were added to the milk replacer during mixing. The 
calves were sorted into four subgroups, with each group receiving a different supplement 
treatment protocol. The first treatment consisted of an addition of 4.00 g/day of Protimax 
® for 7 days then a subsequent reduction which eventually reached 2.00 g/ day for the 
next 14 days (PR); treatment 2 consisted of 2.00 g/day of Betaine 96% added from day 3 
through day 54 (BE); treatment 3 consisted of 4.00 g/day of Protimax ® for 7 days, then 
2.00 g/day for the next 14 days with  2.00 g/day of Betaine 96% added from days 3 thru 
54 (BP); and the fourth treatment served as the control in which the calves received milk 
replacer with no additional supplement (NA).  For the duration of the study, water and 
an 18% calf starter was provided ad libitum.  
 
In order to keep an accurate record of herd growth, BW was recorded bi-weekly on 
Tuesdays at 1800 h and Saturdays at 0600 h. Additionally, calf starter refusals were 
weighed and recorded daily at 1800 h while water intake was also weighed and recorded 
daily at 0600 h.  ADG was calculated at the end of the project by subtracting the 
beginning BW from the end BW and then dividing the total by the number of days in the 
study (54 d).  
 
To maintain adequate herd health, fecal score was recorded each a.m. to serve as an 
indicator of morbidity. Morbidity rate was defined as number of calves treated for a 
disease or illness, while mortality was defined as death or culling from the study due to 
severe disease or illness. At all feedings, each calf was inspected for possible illness.  
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Fecal score was recorded daily using a numbering system from 1-4 (1 = formed, hard; 2 
= pudding consistency; 3 = pancake batter consistency; 4 = mixture of watery liquid and 
solids).  If a calf recorded a high fecal score, the calf received an electrolyte scour 
treatment of Re-Sorb® (Pfizer Animal Health, Exton, PA).   
 
Respiratory rates (RR) were also measured and recorded twice daily at each feeding. 
This also served as a further indicator of morbidity. Calves with abnormal RR were 
treated with a preventative of 3.00 cc of florfenicol (Nuflor®, Intervet, Schering-Plough 
Animal Health Corp., Summit, NJ) given subcutaneously. Furthermore, rectal 
temperature was recorded and evaluated twice daily. Calves with a rectal temperature 
greater than 40 °C were treated orally with 1.00 cc of flunixin meglumine (Banamine®, 
Intervet, Schering-Plough Animal Health Corp., Summit, NJ) to reduce fever and 
possible lung inflammation that has been known to accompany BRD. 
 
On day 54, all calves started the weaning process, at which time the data recording 
ceased. During the 2-day weaning period, the calves received only 2.00 L of milk 
replacer per day with calf starter and water provided ad libitum.   
 
Data analysis 
All recorded data was entered into a spreadsheet program (Excel, Microsoft Corp., 
Redmond, WA, 2003) daily. Data was analyzed in a completely randomized design with 
a 3 X 4 factorial treatment arrangement using an analytical software program (SAS 
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System for Windows, 9.1, SAS Institute Inc., Cary, NC, 2002-2003).  The least square 
means of BW and fecal score were evaluated by PROC MIXED for Repeated Measures 
with metaphylactic agents, milk replacer additives, and metaphylactic agent by milk 
replacer additive serving in the model: 
Yijklm =  + Di + Tj + Ak + TDij +ADik + TAjk + CTjl + eijklm 
 = overall population mean 
D = day effect as a continuous variable (i=1-54) 
T = effect of milk replacer additive (j=1,2,3,4) 
A = effect of metaphylactic agent (k=1,2,3) 
TD = effect of milk replacer additive combined with day 
AD = effect of metaphylactic agent combined with day 
TA = effect of milk replacer additive with metaphylactic agent 
CA = effect of lth calf (l = 1,44) within kth  treatments 
e = the random error term. 
 
ADG, number of treatments for scours, respiratory symptoms, and febrile events were 
analyzed using PROC MIXED with metaphylactic, milk replacer additive, and 
metaphylactic by milk replacer additive as the model: 
Yijkl=  + Ti + Aj + TAij + eijk 
 = overall population mean 
T = effect of milk replacer additive (j=1,2,3,4) 
A =  effect of metaphylactic (k=1,2,3) 
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TA = effect of milk replacer additive with metaphylactic 
e = random error term. 
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CHAPTER III 
 
RESULTS 
 
 
 
Throughout the study, eight of the fifty-two calves had to be culled from the project for 
severe morbidity with five eventually reaching mortality. Data collected on the 
remaining forty-four calves was evaluated and analyzed to reach a conclusion. The 
metaphylactic agents, milk replacer additives, and interactions between the two had no 
profound effect on BW, ADG, or reduction in number of treatments for scours, 
respiratory symptoms, or febrile events. Additionally, fecal score was not affected by 
additives (P>0.18), nor interaction with metaphylaxis (>0.14), but was reduced by 
metaphylaxis (P<0.01) as shown in Tables 1, 2, and 3. 
 
a,b Means without a common superscript were significantly different (P<0.01). 
 
 
 
 
 
Table 1.  LSM for Metaphylaxis      
Variables Micotil Excede Control P-value 
BW (kg)  
47.59 ± 1.57 47.99 ± 1.41 48.99 ± 1.55 0.8042 
ADG (kg) 
0.44 ± 0.04 0.41 ± 0.03 0.46 ± 0.04 0.5903 
Fecal Score 
 2.00 ± 0.04
b 1.86 ± 0.04a 2.03 ± 0.04b 0.0061 
Number of Treatments for Scours 
 7.22  ± 1.18 5.89  ± 1.06 7.42 ±  1.24 0.5787 
Number of Treatments for 
Respiratory Symptoms 
 
0.41±0.15 0.17±0.14 0.50±0.16 0.2632 
Number of Treatments for Febrile 
Events 0.27  ± 0.30 0.83 ±  0.26 0.52  ± 0.31 0.3634 
 12
 
 
Table 2. LSM for Milk Replacer Additive  
Variables PR BE NA BP P-value 
BW (kg) 47.52 ±1.77 47.61±1.72 47.66±1.80 48.42±1.69 0.9809 
ADG (kg) 0.41±0.04 0.44±0.04 0.45±0.04 0.47±0.04 0.7198 
Fecal Score 
 1.97±0.05 1.99±0.04 2.01±0.05 1.88±0.04 0.1860 
Number of Treatments for Scours 
 6.47±1.44 7.93±1.29 7.13±1.35 5.83±1.26 0.6923 
Number of Treatments for Respiratory 
Symptoms 
 
0.69±0.19 0.47±0.17 0.17±0.18 0.11±0.17 0.0931 
Number of Treatments for Febrile 
Events 0.33±0.36 0.69±0.32 0.58±0.34 0.56±0.32 0.9047 
 
 
 
 
 
Table 3. LSM for Metaphylactic with Milk Replacer Additive 
  Micotil   Excede   Control   
Variables PR BE NA BP PR BE NA BP PR BE NA BP P-value 
BW (kg) 48.50 
± 2.74 
49.07 
± 2.45  
45.07 
± 3.85 
46.26 
± 3.15 
45.25 
± 3.15 
46.17 
± 3.15 
49.17 
± 2.45 
49.67 
± 2.25 
48.80 
± 3.15 
47.60 
± 3.15 
48.75 
± 2.74 
49.32 
± 3.15 
0.8088 
ADG (kg) 00.45 
± .06 
00.46 
± .05 
00.37 
± .09  
00.49 
± .07 
00.37 
± .07 
00.36 
± .07 
00.44 
± .05 
00.49 
± .05 
00.40 
± .07 
00.48 
± .07 
00.53 
± .06 
00.43 
± .07 
0.6348 
Fecal Score 1.94  
± .07 
1.94  
± .06 
2.17  
± .09  
1.96  
± .08 
1.84  
± .08 
1.94  
± .08 
1.88  
± .06 
1.72  
± .06 
2.12  
± .08 
2.04  
± .08 
1.97 
± .07 
1.97  
± .08 
0.1427 
Number of 
Treatments 
for Scours 
 
5.75  
± 2.08 
7.80  
± 1.86 
8.00  
± 2.94 
7.33  
± 2.40 
4.67  
± 2.40 
9.00  
± 2.40 
6.40  
± 1.86 
3.50  
± 1.70 
9.00  
± 2.94 
7.00  
± 2.40 
7.00  
± 2.08 
6.67  
± 2.40 
0.8118 
Number of 
Treatments 
for 
Respiratory 
Symptoms 
 
0.75  
± 0.27 
0.40  
± 0.24 
0.50  
± 0.38 
-3.67 
E-16 
± 0.31 
0.33  
± 0.31 
0.33  
± 0.31 
-5.54 
E-17 
± 0.24 
5.86 
E-17 
± 0.22 
1.00  
± 0.39 
0.67  
± 0.31 
7.71 
E-17 
± 0.27 
0.32  
± 0.31 
0.8198 
Number of 
Treatments 
for Febrile 
Events 
0.00  
± 0.52 
0.40  
± 0.46 
3.33 
E-16 
± 0.73 
0.67  
± 0.60 
1.00  
± 0.60 
1.00  
± 0.60 
1.00  
± 0.46  
0.33  
± 0.42 
2.59 
E-16 
± 0.73 
0.67  
± 0.60 
0.75  
± 0.52 
0.67  
± 0.60  
0.8522 
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Metaphylaxis 
The metaphylaxis treatments had no effect on BW (P>0.8) nor ADG (P>0.6). However, 
there was an increase in BW throughout the study indicated in Figure 1. The overall BW 
average (48.17 kg) between TIL (47.59 kg), CEF (47.92 kg), and CON (48.97 kg) is 
demonstrated in Figure 2.  
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Figure 1. Mean BW from day 1- 54 for MG 
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Figure 2. Mean BW for MG 
 
 
 
Figure 3 demonstrates the means of the three groups.  Overall, the calves gained 0.45 
kg/d with averages of: 0.44 kg/d (TIL), 0.41 kg/d (CEF), and 0.46 kg/d (CON). 
 
 
0.38
0.39
0.4
0.41
0.42
0.43
0.44
0.45
0.46
0.47
Antibiotic
A
D
G
 (k
g) Excede
Micotil
Control
Overall
 
Figure 3. ADG for MG 
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Fecal score saw a dramatic increase from day 1 through day 6 and then declined steadily 
for the remainder of the trial.  This event could have been the result of stress or 
environmental changes (Figure 4). It was shown that the fecal scores were reduced by 
39% when CEF was administered when compared to both TIL (P<.01) and CON 
(P<.01). The average fecal score for CEF (1.86) was lower than both TIL (2.00) and 
CON (2.03) as outlined in Figure 5. 
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Figure 4. Mean fecal score from day 1-54 for MG 
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Figure 5. Mean fecal score for MG 
 
 
 
Conversely, there was no significant difference in number of treatments for scours (P > 
0.6), respiratory events (P > 0.2), or febrile events (P > 0.3) when using metaphylaxis. 
Throughout the study, the calves were treated for scours an average of 6.84 in the 
metaphylactic groups. CEF presented the lowest average (5.89) while TIL (7.22) and 
CON (7.42) were similar (Figure 6). Respiratory symptoms treatments were the lowest 
for the CEF group (0.17 treatments), while TIL (0.41), and CON (0.5) were once again 
similar (Figure 7). However, CEF showed the highest average for febrile events (0.83 
treatments) while the overall average was lower (0.54) (Figure 8). 
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Figure 6. Mean number of scours treatments for MG 
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Figure 7. Mean number of respiratory symptoms treatments for MG 
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Figure 8. Mean number of febrile event treatments for MG 
 
 
 
Milk replacer additive 
 
Milk Replacer Additives had no effect on BW (P>0.98), ADG (P>0.7), fecal score 
(P>0.18), respiratory symptoms (P>0.09), febrile events (P>0.9) or a reduction in 
treatments for scours (P>0.69) (Table 2). Figure 9 displays BW ranging from 47.52 kg 
(PR) to 48.42 kg (BP), with a steady increase throughout the study between the four 
groups as outlined in Figure 10. The ADG across treatments was 0.44 kg/d, with PR 
showing the lowest value (0.41 kg/d) and BP showing the highest value (0.47 kg/d) 
(Figure 11).   
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Figure 9. Mean BW for MRA 
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Figure 10. Mean BW from day 1-54 for MRA 
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Figure 11. Mean ADG for MRA 
 
 
 
The same trend observed in the metaphylactic groups is continued in the milk replacer 
additive groups (Figure 12). The overall mean fecal score for the additive groups was 
1.96, with BP having the lowest score (1.88) as shown in Figure 13. 
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Figure 12. Mean fecal score from day 1-54 for MRA 
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Figure 13. Mean fecal score for MRA 
 
 
 
The mean number of respiratory symptoms treatments was the highest in the PR group 
(0.70) and the lowest in the BP group (0.11) with a mean of 0.36 for all groups 
combined (Figure 14). The mean number of scour treatments was 6.84 (Figure 15) while 
the mean number of treatments for febrile events was found to be 0.54 (Figure 16).   
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Figure 14. Mean number of respiratory treatments for MRA 
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Figure 15. Mean number of scours treatments for MRA 
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Figure 16. Mean number of febrile event treatments for MRA 
 
 
 
Metaphylaxis and milk replacer additive interaction 
The interaction of metaphylaxis and milk replacer additive had no effect on the tested 
variables.  Figures 17-34 refer to the metaphylaxis combined with milk replacer for the 
studied variables. All agents caused a variation in BW with CEF ranging from 45.25 kg 
(PR) to 49.67 kg (BP), TIL from 45.07 kg (NA) to 49.07 kg (BE), and CON from 47.6 
kg (BE) to 49.32 kg (BP). ADG also had a variation from 0.36 kg/d (CEF/BE) to 0.54 
kg/d (CON/NA). The fecal score mean was the highest in the TIL/NA groups (2.17) and 
the lowest in the CEF/BP groups (1.71). CEF/BE and CON/PR reflected the same 
number of scour treatments (9.00), whereas CON/BE and CON/NA had slightly lower 
incidents (7.00). The lowest scour treatments were recorded in the CEF/BP mixture 
group (3.50). The highest respiratory treatment mean was documented in the CON/PR 
group (1.00), while CEF/PR, CEF/BE, and CON/BR all showed the same mean (0.33). 
CEF/PR, CEF/BE, CEF/NA all showed a mean of 1.00 treatments for febrile events, 
 24
43
44
45
46
47
48
49
50
51
Excede
Av
g.
 B
W
 (k
g) PR
BE
NA
BP
43
44
45
46
47
48
49
50
Micotil
A
vg
. B
W
 (k
g) PR
BE
NA
BP
TIL/BP, CON/BE, CON/BP had a mean of 0.67 treatments, and the TIL/PR group was 
the lowest with 0.00 treatments.  
         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. Mean BW for CEF (Excede®) with MRA 
 
 
 
 
 
          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. Mean BW for TIL (Micotil®) with MRA     
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Figure 19. Mean BW for CON (Saline) with MRA                      
 
 
 
 
 
 
 
Figure 20. ADG for CEF (Excede®) with MRA 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21. ADG for TIL (Micotil®) with MRA 
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Figure 22. ADG for CON (Saline) with MRA                          
 
 
 
 
           
 
 
 
 
 
 
 
Figure 23. Mean fecal score for CEF (Excede®) with MRA                         
 
 
 
 
 
 
 
 
 
 
 
Figure 24. Mean fecal score for TIL (Micotil®) with MRA     
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Figure 25. Mean fecal score for CON (Saline) with MRA                    
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Figure 26. Mean number of scour treatments for CEF (Excede®) with MRA 
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Figure 27. Mean number of scour treatments for TIL (Micotil®) with MRA         
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Figure. 28. Mean number of scour treatments for CON (Saline) with MRA 
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Figure 29. Mean number of respiratory symptom treatments for CEF (Excede®) with MRA 
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Figure. 30. Mean number of respiratory symptom treatments for TIL (Micotil®) with MRA 
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Figure 31. Mean number of respiratory symptom treatments for CON (Saline) with MRA                                           
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Figure. 32. Mean number of febrile event treatments for CEF (Excede ®) with MRA                                                    
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Figure 33. Mean number of febrile event treatments for TIL (Micotil®) with MRA 
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Figure. 34. Mean number of febrile event treatments for CON (Saline) with MRA    
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CHAPTER IV 
 
SUMMARY AND CONCLUSIONS 
 
 
 
Previous research has shown implementing a metaphylaxis protocol had a positive 
impact on the production of beef cattle by decreasing the incidence and severity of 
disease. Therefore, the treatments usually show a positive correlation to ADG and BW 
(Booker et al., 2006; Galyean et al., 1995; Guthrie et al., 2004). However, the test groups 
showed no significant difference in the variables when treated with metaphylaxis or milk 
replacer additives. This may be due to a lack of disease challenge in the project.   
  
Stress and noninfectious types may be other explanations for scour rates. These causes 
and their subsequent treatments have no correlation with antibiotic treatment. Therefore, 
it is possible for a calf to develop scours and need treatment independent of a 
metaphylactic protocol. In this study, fecal score was the only factor that was 
significantly affected.  On average, calves treated with CEF had a firmer stool than those 
in either the TIL or control groups. This is most likely due to a reduction in the number 
of subclinical pathogens for diseases which cause diarrhea by metaphylactic treatment 
with CEF.  However, this treatment may have been detrimental to the overall health of 
the calves as calves fed milk replacer do not normally have a firm, formed stool. Stress 
(transport, feed change, etc.) and environmental changes may have been the cause of the 
increase in fecal score during the first few days of the study. The change was seen in all 
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groups with a uniform decrease at the same time in all groups, revealing changes that 
were not associated with a metaphylactic, milk replacer additive, or both.  
 
As there was no significant difference between the MG or MRA groups, BW may have 
also had an effect on the results of this study.  Research has shown that heavier calves 
(>39 kg) are less susceptible to morbidity than light weight calves (Fallon et al., 1987; 
Moore et al., 2002).  On of the requirements of the study was that all calves must weigh 
around 45 kg (range 39 – 46 kg), which is well above the weight (~39 kg) that is 
determined to distinguish calves to be more or less susceptible to morbidity and 
mortality. As a result, the calves in this study were less susceptible to disease due the 
fact of having a proper BW. 
 
In addition, Protimax® and Betaine 96% had no affect on the tested variables.  This 
result could have been due to the fact the calves were provided with the necessary 
requirements to maintain adequate health and proper growth.  Colostrum could have 
accounted for the necessary requirements that Protimax® provides, while Betaine 96% 
requirements could have been met through either milk replacer, calf starter, or both. 
 
There was no notable difference in BW, fecal score, ADG, or number of treatments 
between the different milk additive groups. Both additives were designed to target 
specific diseases or metabolic challenges. The calves were not in need of such 
supplementation and therefore, no response was observed. 
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Since the results showed no effect on health and growth of neonatal calves when using 
TIL or CEF as a metaphylactic nor when using a milk replacer additive, further research 
needs to be done in order to assure a proper calf management protocol. Even though 
CEF was shown to reduce fecal score, it should not be widely used in the dairy industry 
without further testing. It is likely that the absence of disease and other, foreign 
pathogens caused the lack of response in the subjects.  In order to determine an accurate 
response, disease should be challenged in a further study. 
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